BioXcel Therapeutics, Inc. — Director's Dealing 2026

Jan 6, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BioXcel Therapeutics, Inc. (BTAI)
CIK: 0001720893
Period of Report: 2026-01-01

Reporting Person: Steinhart Richard I (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2026-01-01	Restricted Stock Units	$	A	70000	Acquired		Common Stock (70000)	Direct

Footnotes

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: On January 1, 2026, the Reporting Person was granted 70,000 RSUs, vesting as to 25% of the underlying shares on the six-month anniversary of the original promise date of November 4, 2025 (the "Vesting Commencement Date"), with the remaining 75% vesting in three equal installments of 25% on the last day of each subsequent six-month period thereafter, such that the RSUs are fully vested on the two-year anniversary of the Vesting Commencement Date, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates.